The majority of trials are early-phase (Phase 1 and 2) studies, reflecting the current stage of development and the clinical complexities of ALK-positive NSCLC, such as high rates of drug resistance and substantial interpatient variability. The gene discussed is ALK; the disease is non-small cell lung carcinoma.